Clinical Trial Update: Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST) [Phase 2]

View source ↗

Summary

A Phase 2 study (LUST) evaluating Lu-PSMA therapy in combination with stereotactic radiotherapy versus radiotherapy alone in prostate cancer is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lu-PSMA-617 (Pluvicto) (Lutetium-177-PSMA-617)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Prostate Cancer | Phase 2 | Status: RECRUITING